Aclarion, Inc. (ACON)
Automate Your Wheel Strategy on ACON
With Tiblio's Option Bot, you can configure your own wheel strategy including ACON - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ACON
- Rev/Share 0.2489
- Book/Share 71.9375
- PB 0.0945
- Debt/Equity 0.0
- CurrentRatio 21.6833
- ROIC -0.3631
- MktCap 3960123.0
- FreeCF/Share -26.4495
- PFCF -0.6825
- PE -0.2249
- Debt/Assets 0.0
- DivYield 0
- ROE -1.269
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Aclarion Announces Texas Back Institute as New CLARITY Trial Site
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic …
Read More
Aclarion Announces Commercial Agreement with Spine Institute of Louisiana
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
Expands access to first customer using Philips MR Spectroscopy (MRS), demonstrating ease of Nociscan integration across multiple MRS platforms Nociscan now commercially available at 17 sites covering eight states and four countries BROOMFIELD, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has established a commercial agreement with the Spine Institute of Louisiana (SIL) in Shreveport, LA.
Read More
Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Independent Cost-Effectiveness Analysis Concludes Nociscan is Effective and Less Costly Compared to Provocative Discography Conclusions Illustrate Nociscan Saves $1,712 per Patient and Improves Surgical Success by 10% BROOMFIELD, Colo., April 21, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a peer-reviewed article in Clinicoeconomics and Outcomes Research titled "The Comparison of Cost-Effectiveness Between Magnetic Resonance Spectroscopy and Provocative Discography in the Identification of Chronic Low …
Read More
Aclarion Provides Shareholder Update
Published: March 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
BROOMFIELD, Colo., March 13, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it has issued an 8k filing that provides an update for stakeholders to review.
Read More
Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey
Published: March 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
BROOMFIELD, Colo., March 06, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today plans to expand Nociscan access across key markets in New York and New Jersey.
Read More
Aclarion, Inc. Announces Adjournment of Special Meeting of Stockholders
Published: February 28, 2025 by: MCAP MediaWire
Sentiment: Neutral
Meeting adjourned to Wednesday, March 5, 2025 at 9:30 a.m. Mountain Time BROOMFIELD, Colo.
Read More
Aclarion, Inc. Announces Adjournment of Special Meeting of Stockholders
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
BROOMFIELD, Colo., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ: ACON) (NASDAQ: ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced that its Special Meeting of Stockholders (the “Special Meeting”) scheduled for February 28, 2025 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company's definitive proxy statement for the Special Meeting, filed with the Securities and Exchange Commission (the “SEC”) on February 3, 2025.
Read More
Aclarion to Showcase Groundbreaking NOCISCAN Technology at the 2025 Spine Summit
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Dr. Nicholas Theodore to highlight NOCISCAN capabilities combining MR Spectroscopy and augmented intelligence (AI) NOCISCAN is an innovative decision support tool that helps physicians personalize treatment for chronic low back pain BROOMFIELD, Colo., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its participation in the 2025 Spine Summit.
Read More
Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Recent Notice of Allowance is for Aclarion's 24th issued US patent Propionic acid (PA) is a biomarker the literature suggests may be indicative of bacterial infection and pain in an intervertebral disc Patent will expand Aclarion's proprietary rights to use MRS to measure propionic acid as a biomarker for the identification of potential infection and pain throughout the body BROOMFIELD, Colo., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, …
Read More
About Aclarion, Inc. (ACON)
- IPO Date 2022-04-22
- Website https://www.aclarion.com
- Industry Medical - Healthcare Information Services
- CEO Brent Ness
- Employees 5